For Immediate Release:

HIGHLAND THERAPEUTICS TO PRESENT DATA AT PRESTIGIOUS SCIENTIFIC MEETINGS

TORONTO, Canada, October 2, 2015—Highland Therapeutics Inc. (“Highland”), a pharmaceutical company, today announced that its wholly owned subsidiary, Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”), will be presenting clinical data and market research findings at the upcoming annual meetings of the Society for Developmental and Behavioral Pediatrics (“SDBP”), being held in Las Vegas, NV, and of the American Academy of Child and Adolescent Psychiatry (“AACAP”), being held in San Antonio, TX.

“The morning routine represents a particularly challenging time for families living with ADHD. While this makes intuitive sense to most practitioners, there is a lack of meaningful research to promulgate informed discussion,” said Dr. Randy Sallee, Ironshore’s Chief Medical Officer. “Much can be learned about the long-term impact of ADHD and its role in shaping family dynamics including the burden on caregivers. Ironshore believes the consequences of not treating patients during this particular time period are profound and intends to bring attention to this important issue. Ironshore invites all physicians attending the SDBP and AACAP conferences to visit with us to learn more about the important work we are doing.”

Details of Ironshore’s poster sessions are below:

**SDBP 2015 Annual Meeting – Las Vegas, NV, October 2-5, 2015**

**Poster #: 1206**

Sunday, October 4, 2015, 6:00pm PDT

A Phase III, 6-Week, Open-Label, Dose-Optimization Study of HLD-200 in Children With Attention-Deficit Hyperactivity Disorder

Presented by Dr. Ann Childress
Poster #: 1208

Monday, October 5, 2015, 1:15pm PDT

Early Morning Functioning in Stimulant-Treated Children and Adolescents With Attention-Deficit Hyperactivity Disorder and Its Impact on Caregivers

Presented by Dr. Randy Sallee

AACAP’s 62nd Annual Meeting – San Antonio, TX, October 26-31, 2015

Poster #: 2.35

Thursday, October 29, 2015, 10:00am CDT

A Phase III Clinical Endpoint Evaluation of HLD200 in Children With ADHD: Safety Results

Presented by Sharon Wigal, Ph.D.

Specific information about the data contained in the posters is embargoed until the start of the meeting.

Commenting on HLD-200, Dr. Ann Childress, principal investigator of HLD-200’s exploratory Phase III study said, “The morning routine is a chaotic time when patients and caregivers attempt to manage a myriad of tasks. A source of significant conflict between parent and child are the struggles to stay on task and on time. These difficulties are exacerbated by the lack of symptom control afforded by available stimulant medications, which are used as first-line therapy. HLD-200, if approved, may become a preferred option for many families because its formulation allows the patient to be dosed at night to target onset upon awakening.”

About Highland Therapeutics Inc.

Highland Therapeutics Inc. is a pharmaceutical company that, through its wholly owned subsidiary Ironshore Pharmaceuticals & Development, Inc., is leveraging its proprietary technology, DELEXIS®, to optimize the delivery of previously approved drug products. The Company’s lead product candidates, HLD-200 and HLD-100, are novel formulations of the psychostimulants (methylphenidate and amphetamine, respectively) used to treat ADHD and are being developed to address a prevalent unmet medical need in the treatment of the disease – inadequate symptom control during the morning routine. Intended for nighttime dosing, DELEXIS® is designed to provide a consistent delay in the initial release of the active drug,
followed by a period of extended release; with the objective of providing control of ADHD symptoms immediately upon waking and throughout the day.

Highland Therapeutics Inc. is a client of MaRS Discovery District’s Health Venture Services group, which provides advisory services, connections to talent, customer & capital networks, and market intelligence to high-impact, Ontario-based life sciences ventures, helping them commercialize their ideas and build globally competitive companies.

For further information, please visit the Company’s website at www.highlandtherapeutics.com, or contact:

    Nelson F. Isabel  
    Chief Financial Officer  
    (647) 260-7875

Forward-Looking Statements

This press release contains forward-looking information, which reflects Highland’s current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Highland’s control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. These forward-looking statements are made as of the date of this press release and, except as expressly required by applicable law, Highland assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.